Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bradley Mcgregor"'
Autor:
Svenja Petersohn, Bradley McGregor, Sven L Klijn, Jessica R May, Flavia Ejzykowicz, Murat Kurt, Matthew Dyer, Bill Malcolm, Sebastien Branchoux, Katharina Nickel, Saby George, Sonja Kroep
Publikováno v:
Journal of Comparative Effectiveness Research (2023)
Aim: Network meta-analyses (NMAs) increasingly feature time-varying hazards to account for nonproportional hazards between different drug classes. This paper outlines an algorithm for selecting clinically plausible fractional polynomial NMA models.
Externí odkaz:
https://doaj.org/article/f4ab129d0b404efd8c4b62efb4d76780
Autor:
Akram M. Shayeb, Hannah Dzimitrowicz McManus, Danielle Urman, Chinmay Jani, Tian Zhang, Nazli Dizman, Luis Meza, Akhilesh Sivakumar, Chun L. Gan, Pedro Barata, Mehmet A. Bilen, Xin Gao, Daniel Heng, Sumanta Pal, Ravi Narra, Deepak Kilari, Marina D. Kaymakcalan, Bradley McGregor, Toni K. Choueiri, Rana R. McKay
Publikováno v:
Clinical Genitourinary Cancer. 21:55-62
In patients with renal cell carcinoma (RCC) on cabozantinib, venous thromboembolism (VTE) management remains challenging due to limited safety data regarding direct oral anticoagulants (DOACs) use in conjunction with cabozantinib. We investigated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d82e8d85323b5ad0eb01e7c727607902
https://doi.org/10.1016/j.clgc.2022.10.013
https://doi.org/10.1016/j.clgc.2022.10.013
Autor:
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert Motzer, Bradley McGregor, Richard J. Lee, Rohit K. Jain, Nancy Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda Sánchez, Robert Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier
Publikováno v:
JAMA oncology. 8(10)
ImportanceDysregulated metabolism is a hallmark of renal cell carcinoma (RCC). Glutaminase is a key enzyme that fuels tumor growth by converting glutamine to glutamate. Telaglenastat is an investigational, first-in-class, selective, oral glutaminase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d814d8a9fe7e9265f06d2c12c2ccd89d
https://pubmed.ncbi.nlm.nih.gov/36048459
https://pubmed.ncbi.nlm.nih.gov/36048459
Autor:
Neeraj, Agarwal, Bradley, McGregor, Benjamin L, Maughan, Tanya B, Dorff, William, Kelly, Bruno, Fang, Rana R, McKay, Parminder, Singh, Lance, Pagliaro, Robert, Dreicer, Sandy, Srinivas, Yohann, Loriot, Ulka, Vaishampayan, Sanjay, Goel, Dominic, Curran, Ashok, Panneerselvam, Martin, Schwickart, Toni K, Choueiri, Sumanta, Pal
Publikováno v:
The Lancet Oncology. 23:899-909
Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide). We aimed to evaluate cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ddb275340bd775c1736462f3dd460a
https://doi.org/10.1016/s1470-2045(22)00278-9
https://doi.org/10.1016/s1470-2045(22)00278-9
Autor:
Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, Cristina Suárez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I. Blum, Viviana Del Tejo, Melissa Hamilton, Jessica R. May, Ella X. Du, Aozhou Wu, Pavol Kral, Cristina Ivanescu, Andi Chin, Keith A. Betts, Chung-Han Lee, Toni K. Choueiri, David Cella, Camillo Porta
Publikováno v:
European Urology Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbf4b42a283a34e4313b7163bcedee06
https://doi.org/10.1016/j.euo.2023.01.012
https://doi.org/10.1016/j.euo.2023.01.012
Autor:
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo
Publikováno v:
Scientia
Background Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a1624d6b56737a87630493fac99671
https://hdl.handle.net/11351/9391
https://hdl.handle.net/11351/9391
Autor:
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Naveen S Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas Hutson, Carlos Alemany, Bradley McGregor, Thomas Powles, Viktor Grünwald, Boris Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C Goh, Michael Staehler, Jaime R Merchan, Ran Xie, Rodolfo F Perini, Kalgi Mody, Jodi McKenzie, Camillo G Porta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c2da15b8e2e8a92751b8777549e5fec
https://www.ncbi.nlm.nih.gov/pubmed/36858721
https://www.ncbi.nlm.nih.gov/pubmed/36858721
Autor:
Bradley Mcgregor, Toni Choueiri, Neil Shah, Aung Bajaj, Jad Chahoud, Bert O’Neil, Joel Michalski, Benjamin Garmezy, Lixian Jin, Usman Aziz, Fiona Xu, Robert Motzer
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0798c7376c7e13e57c03a1b3756010c
https://doi.org/10.1136/jitc-2022-sitc2022.0742
https://doi.org/10.1136/jitc-2022-sitc2022.0742
Autor:
Stephanie Berg, Bradley McGregor
Publikováno v:
Cancers. 14(24)
Treatment advances in kidney cancer continually evolve. The focus of treatment options continues with oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) or intravenous immune checkpoint inhibitors (ICIs). Multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b09f8a0d6293c6a1ddb3be1048a95b
https://pubmed.ncbi.nlm.nih.gov/36551504
https://pubmed.ncbi.nlm.nih.gov/36551504
Autor:
Karl H. Tully, Sebastian Berg, Marco Paciotti, Florian Janisch, Stephen W. Reese, Joachim Noldus, Shahrokh F. Shariat, Toni Choueiri, Guido Müller, Bradley McGregor, Steven L. Chang, Quoc-Dien Trinh, Matthew Mossanen
Publikováno v:
Clinical genitourinary cancer.
Sarcomatoid differentiation in patients diagnosed with renal cell carcinoma (sRCC) imply aggressive behavior and often metastatic disease at the time of diagnosis. We aim to examine the overall survival (OS) in patients with sRCC using the National C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e1b63d2ca503459f549db296851227
https://pubmed.ncbi.nlm.nih.gov/36517393
https://pubmed.ncbi.nlm.nih.gov/36517393